Multiple myeloma, also known as myeloma or plasma cell myeloma, is a progressive hematologic
disease. Complications of multiple myeloma include renal insufficiency, hematologic
complications (anemia, bone marrow failure, bleeding disorders), infections, bone
complications (pathologic fractures, spinal cord compression, hyercalcemia), and neurologic
complications (spinal cord and nerve root compression, intracranial plasmacytomas,
leptomeningeal involvement, among others). This article reviews these various complications
connected to multiple myeloma, examining their various causes and possible treatment.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Hematology/Oncology ClinicsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Renal failure in multiple myeloma. Pathogenesis and prognostic implications.Arch Intern Med. 1990; 150: 1693-1695
- Renal failure in multiple myeloma. Presenting features and predictors of outcome in a series of 94 patients.Arch Intern Med. 1998; 158: 1889-1893
- Management of renal, hematologic, and infectious complications.in: Malpas J.S. Bergsagel D.E. Kyle R.A. Myeloma: biology and management. 3rd edition. Saunders, Elsevier Inc., Philadelphia2004: 251-267
- Renal lesions in multiple myeloma: their relationship to associated protein abnormalities.Am J Kidney Dis. 1983; 4: 423-438
- Pathogenesis and treatment of myeloma kidney.J Lab Clin Med. 1994; 124: 484-488
- Treatment of renal failure associated to multiple myeloma.Arch Intern Med. 1990; 150: 863-869
- “Idiopathic” Bence Jones proteinuria: long-term follow-up in seven patients.N Engl J Med. 1982; 306: 564-567
- Patients with multiple myeloma and renal failure requiring long-term dialysis: presenting features, response to therapy, and outcome in a series of 20 cases.Br J Haematol. 1995; 91: 854-859
- Immunoglobulin D multiple myeloma: presenting features, response to therapy, and survival in a series of 83 patients.J Clin Oncol. 1994; 12: 2398-2404
- Manifestations of systemic light chain deposition.Am J Med. 1976; 60: 293-299
- Biology and therapy of immunoglobulin deposition diseases.Hematol Oncol Clin North Am. 1997; 11: 89-110
- Acquired Fanconi syndrome is an indolent disorder in the absence of overt multiple myeloma.Blood. 2004; 104: 40-42
- Reversible renal insufficiency in multiple myeloma.Arch Intern Med. 1982; 142: 2083-2086
- Renal failure in multiple myeloma: a study of the presenting findings, response to treatment, and prognosis in 26 patients.Nouv Rev Fr Hematol. 1986; 28: 147-152
- Acute renal failure in patients with multiple myeloma.Am J Med. 1984; 76: 247-256
- Chronic dialysis in patients with multiple myeloma and renal failure: a worthwhile treatment.Q J Med. 1989; 270: 903-910
- The role of continuous ambulatory peritoneal dialysis in end-stage renal failure due to multiple myeloma.Am J Kidney Dis. 1990; 6: 216-223
- Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study.Blood. 2007; 109: 2604-2606
- Results of autologous stem cell transplantation in multiple myeloma patients with renal failure.Br J Haematol. 2001; 114: 822-829
- Long-term survival in patients with acute and severe renal failure due to multiple myeloma.Clin Nephrol. 1990; 34: 247-254
- Management of myeloma kidney: an anti-light-chain approach.Am J Kidney Dis. 1987; 10: 28-33
- Prognostic factors and effectiveness of treatment in acute renal failure due to multiple myeloma: review of 50 cases.Clin Nephrol. 1987; 28: 1-9
- Plasma exchange when myeloma presents as acute renal failure. A randomized, controlled trial.Ann Intern Med. 2005; 143: 777-784
- Review of 1027 patients with newly diagnosed multiple myeloma.Mayo Clin Proc. 2003; 78: 21-33
- Initial treatment of multiple myeloma: long-term results in 914 patients.Hematol J. 2001; 2: 272-278
Mecharchand J. Management of haematological complications of myeloma. In: Malpas JS, Bergsagel DE, Kyle RA, et al, editors. Myeloma: biology and management. 2nd edition. Oxford: Oxford University Press. p. 332–57.
- Erythropoiesis in multiple myeloma: defective red cell production due to inappropriate erythropoietin production.Br J Haematol. 1992; 82: 648-653
- Use of epoietin in patients with cancer: evidence-based clinical pactice guidelines of the American Society of Clinical Oncology and the American Society of Hematology.Blood. 2002; 100: 2303-2320
- Use of epoietin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology.J Clin Oncol. 2002; 2: 40-83
- The chemotherapy of plasma cell myeloma and the incidence of acute leukemia.N Engl J Med. 1979; 301: 743-748
- Plasma cell neoplasms and acute leukemia.Clin Haematol. 1982; 11: 221-234
- Acute leukemia and other secondary neoplasms in patients treated with conventional chemotherapy for multiple myeloma: a Finnish Leukemia Group study.Eur J Haematol. 2000; 65: 123-127
- A comparison of the incidence of myelodysplastic syndrome and acute leukemia following melphalan and cyclophosphamide treatment for multiple myeloma.Br J Cancer. 1987; 55: 523-529
- Preceding standard therapy is the likely cause of MDS after autotransplants in multiple myeloma.Br J Haematol. 1996; 95: 349-353
- Infections: principle of prevention and therapy.in: Metha J. Singhal S. Myeloma. Martin Dunitz Ldt, London2002: 223-239
- Biphasic pattern of bacterial infection in multiple myeloma.Ann Intern Med. 1982; 96: 47-50
- Current pattern of infection in multiple myeloma.Am J Med. 1972; 52: 87-92
- Changing pattern of infection in patients with multiple myeloma.Oncology. 1982; 39: 78-82
- Immunological factors and risk of infection in plateau phase myeloma.J Clin Pathol. 1995; 48: 260-266
- Influence of treatment and response status on infection in multiple myeloma.Am J Med. 1981; 71: 935-940
- Frequency of infection in plateau-phase multiple myeloma.Lancet. 1994; 344 ([Letter to the Editor]): 262
- Prophylactic antibiotics for the prevention of early infection in multiple myeloma.Am J Med. 1996; 100: 624-628
- Risk factors for bacterial infections in chronic haemodialysis adult patients: a multicenter prospective survey.Nephrol Dial Transplant. 1995; 10: 377-381
- Role of gammaglobulin for immunoprophylaxis in multiple myeloma.N Engl J Med. 1967; 277: 1336-1340
- Synergistic interactions between interleukin 1, tumor necrosis factor, and lymphotoxin in bone resorption.J Immunol. 1987; 138: 1464-1468
- Comparison of interleukin-1 beta expression by in situ hybridization in monoclonal gammopathy of undetermined significance and multiple myeloma.Blood. 1999; 93: 300-305
- The role of interleukin-1 beta in the pathogenesis of multiple myeloma.Hematol Oncol Clin North Am. 1999; 13: 1117-1125
- Interleukin-6 in human multiple myeloma.Blood. 1995; 85: 863-872
- RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism.Proc Natl Acad Sci USA. 2000; : 1566-1571
- Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials.J Clin Oncol. 2001; 19: 558-567
- Randomized, placebo-controlled multicentre trial of clodronate in multiple myeloma.Lancet. 1992; 340: 1049-1052
- A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma.Br J Haematol. 1998; 100: 317-325
- Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma.N Engl J Med. 1996; 334: 488-493
- Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double blinded, comparative trial.Cancer J. 2001; 7: 377-387
- American Society of Clinical Oncology practice guidelines: the role of bisphosphonates in multiple myeloma.J Clin Oncol. 2002; 20: 3719-3736
- Mayo Clinic consensus statement for the use of bisphosphonates in multiple myeloma.Mayo Clin Proc. 2006; 81: 1047-1053
- Osteonecrosis of the jaw and bisphosphonates.N Engl J Med. 2005; 353 ([letter]): 99-100
- Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors.J Clin Oncol. 2006; 24: 945-952
- Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors.J Clin Oncol. 2005; 23: 8580-8587
- Systematic review: bisphosphonates and osteonecrosis of the jaws.Ann Intern Med. 2006; 144: 753-761
- Neurological manifestations of myeloma and their management.in: Malpas J.S. Bergsagel D.E. Kyle R.A. Myeloma: biology and management. 3rd edition. Saunders, Elsevier Inc., Philadelphia2004: 269-293
- Cancer and nervous system. The neurological manifestations of systemic malignant disease.Blackwell Scientific Publications, Oxford1982
- Back pain and epidural spinal cord compression.Med Clin North Am. 1987; 71: 185-205
- Multiple nerve palsies as the presenting feature of meningeal myelomatosis.Cancer. 1982; 49: 1710-1712
- Paraproteinemias and multiple myeloma.in: Bryn V. Handbook of clinical neurology. Elsevier North Holland Biomedical Press, Amsterdan1980: 131-179
- Myeloma of the central nervous system: strong association with unfavorable chromosomal abnormalities and other high-risk disease features.Leuk Lymphoma. 2004; 45: 291-300
- Peripheral neuropathy associated to antiMAG antibodies.Crit Rev Neurobiol. 1988; 3: 301-332
- Long term prognosis of neuropathy associated with antiMAG IgM M-proteins and its relationship to immune therapies.Brain. 2000; 123: 710-717
- Therapy of neuropathy associated with antiMAG IgM monoclonal gammopathy with Rituxan.Neurology. 1999; 52: a551
- IgM antibody related polyneuropathies: B-cell depletion chemotherapy using rituximab.Neurology. 1999; 52: 1701-1704
- Long-term results of thalidomide in refractory and relapsed multiple myeloma with emphasis on response duration.Eur J Haematol. 2006; 77: 486-492
- Frequency, characteristics and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib.J Clin Oncol. 2006; 24: 3113-3120
Article info
Identification
Copyright
© 2007 Elsevier Inc. Published by Elsevier Inc. All rights reserved.
